866-274-4009 Contact Us

New White Paper: Characterization of Advanced Therapies – Leveraging Advanced Analytics to Avoid FDA Holds

August 1, 2022

Dana Cipriano, Senior Vice President of Testing and Analytical Services & Alexei Saveliev, Director of NGS Lab Operations

CBM experts Dana Cipriano, SVP of Testing and Analytical Services & Alexei Saveliev, Dir. of NGS Lab Operations, explore the latest strategies and technologies to develop a comprehensive, optimal approach to assay development and product characterization.

View the Talk.

In this talk our experts cover on topics related to:

. CQA selection & assay development
. Orthogonal methods for product characterization
. Characterization of on-target gene editing efficiencies and risks of off-target effects
. Next-generation sequencing (NGS) for product characterization from discovery to clinic

View the Talk.

In need of immediate assistance for your product development? Contact us here or simply call to speak with a CBM expert: 866-274-4009.

Contact Us Now